Metabotropic and Enzyme-Linked Receptor Pharmacology

Classification of Receptors by Location and Ligand Properties

Conceptual Overview: * Receptors are categorized into two primary types based on their location: those situated on the cell surface and those located inside the cell (intracellular). * The choice of receptor location depends on the chemical properties of the ligand (the messenger molecule).
Cell Surface Receptors: * Ligand Properties: These receptors bind ligands that are hydrophilic (water-soluble) and lipophobic (fat-insoluble). * Mechanism: Because the cell membrane is a phospholipid bilayer, it acts as a barrier to hydrophilic proteins. These ligands cannot pass through the fat-rich membrane into the cell; therefore, they must bind to a receptor on the surface to trigger activity inside. * Types: Enzyme-linked, metabotropic (GPCRs), and ionotropic receptors.
Intracellular Receptors: * Ligand Properties: These ligands are lipophilic (fat-soluble) and can dissolve in the lipids of the cell membrane. * Mechanism: They pass through the membrane directly, typically traveling to the nucleus to affect gene transcription and protein synthesis.

Detailed Anatomy and Genomics of G-Protein Coupled Receptors (GPCRs)

Definition: GPCR stands for G-protein coupled receptors. The "G" stands for guanine nucleotide binding protein.
Prevalence and Importance: * GPCRs are the most common receptors in the body. * Approximately $4\%$ of the entire mammalian protein-coding genome (roughly $800$ genes) encodes these receptors. * They are involved in a vast array of physiological processes, including heart rate regulation (increase/decrease), bronchoconstriction, bronchodilation, and light detection by rhodopsin in the retina. * Currently, $40\%$ of all modern pharmacological drugs target GPCRs.
Physical Structure: * GPCRs consist of a single polypeptide chain. * They are characterized by seven transmembrane helixes (seven-pass transmembrane protein). * Binding Domains: The ligand can bind either to the extracellular domain (the part outside the cell) or within the pocket created by the transmembrane domains (the helixes within the membrane).
The G-Protein Complex: * The G-protein itself is heterotrimeric, meaning it has three distinct subunits: alpha ( $\alpha$ ), beta ( $\beta$ ), and gamma ( $\gamma$ ). * Subunits of Interest (Alpha): The $\alpha$ subunit is categorized into three main types based on its function: * $G_s$ : Stimulatory; it stimulates the enzyme adenylate cyclase. * $G_i$ : Inhibitory; it inhibits adenylate cyclase. * $G_q$ : Activates the enzyme phospholipase C ( $PLC$ ).

The G-Protein Recycling and Activation Cycle

Inactive State: In its resting state, the $\alpha$ subunit of the G-protein is bound to GDP (guanosine diphosphate).
Activation Step: 1. A ligand binds to the extracellular side of the GPCR. 2. This binding causes a conformational (shape) change in the receptor. 3. The change allows the G-protein to exchange its bound GDP for GTP (guanosine triphosphate).
Dissociation: Once bound to GTP, the $\alpha$ subunit separates from the $\beta$ and $\gamma$ subunits. The $\alpha$ -GTP complex moves along the membrane to interact with effector enzymes.
Signal Output: The $\alpha$ unit (and sometimes the $\beta/\gamma$ complex) activates effector enzymes like adenylate cyclase or phospholipase C to produce second messengers.
Termination (Switching Off): 1. The $\alpha$ subunit has intrinsic enzymatic activity that hydrolyzes GTP back into GDP. 2. Once GTP becomes GDP again, the $\alpha$ subunit becomes inactive and recombines with the $\beta$ and $\gamma$ subunits. 3. The system returns to its original state, ready for another ligand signal.

Second Messenger Systems and Downstream Effects

Adenylate Cyclase Pathway: * $G_s$ (Stimulatory): Increases cyclic adenosine monophosphate ( $cAMP$ ). * $G_i$ (Inhibitory): Decreases $cAMP$ levels. * Role: $cAMP$ often activates Protein Kinase A ( $PKA$ ), leading to phosphorylation and cellular responses.
Phospholipase C Pathway ( $G_q$ ): * Activates Phospholipase C ( $PLC$ ), which cleaves membrane phospholipids into two separate second messengers: 1. $IP_3$ (Inositol triphosphate): Triggers the release of calcium ( $Ca^{2+}$ ) from the endoplasmic reticulum. 2. $DAG$ (Diacylglycerol): Activates Protein Kinase C ( $PKC$ ).
Ion Channel Modulation: * Some GPCRs act as ion channel-linked receptors (distinct from ionotropic receptors). They do not open directly; instead, the G-protein interacts with the ion channel to cause depolarization or hyperpolarization. * Example: Muscarinic receptors for acetylcholine ( $ACh$ ) in the heart or sweat glands.

Structure-Activity Relationship (SAR): The Asthma Case Study

SAR Definition: Tweak/modify the chemical structure of a drug to achieve specific selectivity or potency.
The Problem with Noradrenaline: * Noradrenaline is a potent but non-selective endogenous agonist. It binds to both $\alpha$ and $\beta$ adrenergic receptors. * In the lungs, we want bronchodilation (mediated by $\beta_2$ receptors). * Noradrenaline is a small molecule; it fits into the "pockets" of both $\alpha$ and $\beta$ receptors. It may cause bronchodilation, but it also causes unwanted $\alpha$ -mediated effects (like vasoconstriction).
The SAR Solution (Bulky Groups): 1. Hydroxyl groups: Increasing $-OH$ groups on the benzene ring increases hydrogen bonding, enhancing affinity and potency, but not necessarily selectivity. 2. Size/Bulky Groups: Pharmacologists found that the $\beta_2$ receptor can accommodate larger molecules than the $\alpha$ receptor. 3. Isoprenaline: By adding a bulky group to the nitrogen of Noradrenaline, the molecule becomes too big for the $\alpha$ receptor but remains active at both $\beta_1$ (heart) and $\beta_2$ (lungs). 4. Salbutamol: Further structural modifications lead to Salbutamol, which is highly selective for $\beta_2$ receptors. This allows for bronchodilation to treat asthma without significantly altering heart rate ( $\beta_1$ ) or blood pressure ( $\alpha$ ).

Enzyme-Linked Receptors: Receptor Tyrosine Kinases (RTKs)

Primary Example: Insulin Receptor: * These are cell surface receptors that bind hydrophilic, lipophobic ligands like insulin.
Structure: * Alpha (\alpha) Subunit: Located outside the cell; acts as the binding domain for the ligand. * Beta (\beta) Subunit: Located inside the cell; linked to an enzyme (kinase).
Mechanism (Receptor Dimerization): 1. The ligand (e.g., insulin) binds to the $\alpha$ subunit. 2. This causes dimerization—two receptor units come together to form a pair. 3. The intracellular $\beta$ subunits then perform autophosphorylation (phosphorylating their own tyrosine residues). 4. These phosphorylated sites act as docking points for other intracellular proteins.
Cellular Response (Glucose Uptake): * The signaling cascade triggers the exocytosis of glucose transporter proteins (GLUT4) to the cell membrane. * GLUT4 then facilitates the entry of glucose into the cell.

Questions & Discussion

Question: Does insulin bind to a G-protein receptor? * Answer: No. Insulin is an enzyme-linked receptor, not a GPCR.
Question: Is adrenaline a G-protein receptor ligand? * Answer: Yes, adrenaline binds to adrenergic GPCRs. It signals the $\alpha$ subunit to switch to GTP, which can then signal myocytes (muscle cells) to accelerate (increase heart rate).
Metaphor/Analogy: A student compared SAR to keys and locks. A master key might open every lock (noradrenaline), but by tweaking the shape of the key (Salbutamol), you create a specific key that only opens one specific lock ( $\beta_2$ ).
Scenario (Canine Asthma): * If a cat or dog presents with a bronchospasm (narrowed lungs), the immediate goal is bronchodilation. * Stimuli for asthma can include pollen or dust, which causes allergic reactions in sensitive individuals. * Treatments discussed include Salbutamol (selective $\beta_2$ agonist) and Antihistamines (specifically targeting $H_1$ receptors for allergic reactions, rather than $H_2$ ).
Extended Matching Practice: * Adenylate Cyclase: The enzyme activated by the $G_s$ pathway that converts $ATP$ into the second messenger $cAMP$ . * cAMP: The second messenger produced by adenylate cyclase that activates Protein Kinase A ( $PKA$ ). * $G_i$ : The subtype that inhibits adenylate cyclase and reduces $cAMP$ levels. * Phospholipase C ( $PLC$ ): The enzyme downstream of $G_q$ that cleaves phospholipids into $IP_3$ and $DAG$ . * $IP_3$ : The second messenger that triggers calcium release from the endoplasmic reticulum. * $\beta_2$ Adrenergic Receptor: The specific GPCR on bronchial smooth muscle that Noradrenaline and Salbutamol bind to for bronchodilation.